Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells

British Journal of Haematology

Volumn 171, Issue 2, 2015, Pages 205-209

  Evans, Andrew G ^a   Rothberg, Paul G ^a   Burack, W Richard ^a   Huntington, Scott F ^b   Porter, David L ^b   Friedberg, Jonathan W ^a   Liesveld, Jane L ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chimeric antigen receptor T cells; Chronic lymphocytic leukaemia; Leukaemia; Lymphoma; Plasmablastic

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE; TISAGENLECLEUCEL T;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPH NODE BIOPSY; LYMPHOCYTE DIFFERENTIATION; MALE; MOLECULAR GENETICS; PLASMA CELL; PLASMABLASTIC LYMPHOMA; PLASTICITY; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84942983455     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13562     Document Type: Article

References (15)

1. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Scheinberg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M. & Sadelain, M. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118, 4817-4828.
2. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I.V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M. & Sadelain, M. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine, 5, 177ra138.
3. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
4. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C., Levine, B.L. & June, C.H. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368, 1509-1518.
5. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., Yang, J.C., Kammula, U.S., Devillier, L., Carpenter, R., Nathan, D.A., Morgan, R.A., Laurencot, C. & Rosenberg, S.A. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 119, 2709-2720.
6. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., Raffeld, M., Feldman, S., Lu, L., Li, Y.F., Ngo, L.T., Goy, A., Feldman, T., Spaner, D.E., Wang, M.L., Chen, C.C., Kranick, S.M., Nath, A., Nathan, D.A., Morton, K.E., Toomey, M.A. & Rosenberg, S.A. (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology, 33, 540-549.
7. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S. & Mackall, C.L. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 385, 517-528.
8. Martinez, D., Valera, A., Perez, N.S., Sua Villegas, L.F., Gonzalez-Farre, B., Sole, C., Gine, E., Lopez-Guillermo, A., Roue, G., Martinez, S., Sant, F., Warzocha, K., Robak, T., Czader, M., Villamor, N., Colomo, L., Campo, E. & Martinez, A. (2013) Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases. American Journal of Surgical Pathology, 37, 272-281.
9. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L. & Grupp, S.A. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371, 1507-1517.
10. Maus, M.V., Grupp, S.A., Porter, D.L. & June, C.H. (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123, 2625-2635.
11. Meeker, T., Lowder, J., Cleary, M.L., Stewart, S., Warnke, R., Sklar, J. & Levy, R. (1985) Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. New England Journal of Medicine, 312, 1658-1665.
12. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P. & Olivier, M. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation, 28, 622-629.
13. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 365, 725-733.
14. van Zelm, M.C., Reisli, I., van der Burg, M., Castano, D., van Noesel, C.J., van Tol, M.J., Woellner, C., Grimbacher, B., Patino, P.J., van Dongen, J.J. & Franco, J.L. (2006) An antibody-deficiency syndrome due to mutations in the CD19 gene. New England Journal of Medicine, 354, 1901-1912.
15. van Zelm, M.C., Smet, J., Adams, B., Mascart, F., Schandene, L., Janssen, F., Ferster, A., Kuo, C.C., Levy, S., van Dongen, J.J. & van der Burg, M. (2010) CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. Journal of Clinical Investigation, 120, 1265-1274.